{"doi":"10.5551/jat.63789","title":"Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan","abstract":null,"journal":"Journal of Atherosclerosis and Thrombosis","year":2023,"id":29187,"datarank":0.48984104243233056,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"self_citation_contribution":0.32958368660043297,"citation_network_contribution":0.1602573558318976,"self_endowment_contribution":0.32958368660043297,"citer_contribution":0.1602573558318976,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":7,"citers_with_citation_signal":4,"citers_with_endowment":4,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":161540,"name":"Yen-Wen Wu","orcid":null,"position":1,"is_corresponding":false},{"id":161541,"name":"Chao-Feng Lin","orcid":null,"position":2,"is_corresponding":false},{"id":161542,"name":"Hung-I Yeh","orcid":null,"position":3,"is_corresponding":false},{"id":161543,"name":"Wei-Ting Chang","orcid":null,"position":4,"is_corresponding":false},{"id":161544,"name":"Min-Ji Charng","orcid":null,"position":5,"is_corresponding":false},{"id":161545,"name":"Po-Hsun Huang","orcid":null,"position":6,"is_corresponding":false},{"id":161546,"name":"Chih-Chan Lin","orcid":null,"position":7,"is_corresponding":false},{"id":161547,"name":"Tsung-Hsien Lin","orcid":null,"position":8,"is_corresponding":false},{"id":161548,"name":"Wei-Wen Lin","orcid":null,"position":9,"is_corresponding":false},{"id":161549,"name":"I-Chang Hsieh","orcid":null,"position":10,"is_corresponding":false},{"id":161550,"name":"Feng-Yu Kuo","orcid":null,"position":11,"is_corresponding":false},{"id":161552,"name":"Ching-Pei Chen","orcid":null,"position":12,"is_corresponding":false},{"id":161554,"name":"Yi-Heng Li","orcid":null,"position":13,"is_corresponding":false},{"id":161539,"name":"Po-Lin Lin","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36418110","pmcid":"PMC10499444","openalex_id":"https://openalex.org/W4310335042","authors":[],"funders":[],"total_grants":0,"fwci":1.3089,"citation_percentile":0.80635522,"influential_citations":2,"citation_trend":[{"year":2023,"count":3},{"year":2024,"count":1},{"year":2025,"count":2},{"year":2026,"count":2}],"oa_status":"gold","license":"cc-by-nc-sa","oa_locations":[{"url":"https://www.jstage.jst.go.jp/article/jat/advpub/0/advpub_63789/_pdf","host_type":"journal"},{"url":"https://www.jstage.jst.go.jp/article/jat/advpub/0/advpub_63789/_pdf","host_type":"GOLD"},{"url":"https://www.jstage.jst.go.jp/article/jat/advpub/0/advpub_63789/_pdf","host_type":"publisher"},{"url":"https://www.jstage.jst.go.jp/article/jat/30/9/30_63789/_pdf","host_type":"publisher"},{"url":"https://doi.org/10.5551/jat.63789","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/36418110","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10499444","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10499444/pdf/jat-30-1123.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC10499444","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC10499444?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Lipoproteins and Cardiovascular Health","Coronary Interventions and Diagnostics","Cardiac Imaging and Diagnostics","Medicine","Humans","Male","Adult","Middle Aged","Aged","Proprotein Convertase 9","Cholesterol, LDL","Antibodies, Monoclonal","Retrospective Studies","Taiwan","Hydroxymethylglutaryl-CoA Reductase Inhibitors","Subtilisins"],"mesh_terms":["Proprotein Convertase 9","Adult","Aged","Antibodies, Monoclonal","Humans","Cholesterol, LDL","Male","Middle Aged","Retrospective Studies","Subtilisins","Taiwan","Hydroxymethylglutaryl-CoA Reductase Inhibitors"],"keywords":["Kexin","PCSK9","Proprotein convertase","Subtilisin","Medicine","Proprotein Convertases","Pharmacology","Internal medicine","Cholesterol","Lipoprotein","LDL receptor","Chemistry","Biochemistry","Enzyme","Statin","efficacy","Pcsk9 Inhibitor"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-08T22:50:30.312974Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}